http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-3021223-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c9d4fe8400cd819dbfd3877861098f1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-899 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-758 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-899 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-758 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-41 |
| filingDate | 2014-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39e72b582b4c039151e050ba01f7a6c9 |
| publicationDate | 2015-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-3021223-A1 |
| titleOfInvention | PHYTOMEDICAMENT AGAINST CANCER |
| abstract | A well-tolerated solid or liquid pharmaceutical compound is a combination of African plants with synergistic actions against benign prostatic hypertrophy and prostate cancer, it is an association of four plants that are: 'Azadirachta indica widely used (as well as its oil) in the treatment of cancers, roots of Fagara Xanthoxyloides commonly used against leukemias, roots of Imperata cylindrica widely used in different types of cancer, Kalanchoe pinata roots (still called plant of the resurrection) very used in cases of diseases deemed incurable. This product is obtained by first drying these different roots and seeds in the shade. Then they are crushed, sieved to obtain a fine powder. The various powders are mixed and distributed in empty capsules that have been thoroughly cleaned and put in small bottles of 20, 50 or 100 capsules. Solid pharmaceutical compound may be more concentrated and then supplemented with a solvent. Then each vial is placed in a suitable device for about a week. The enriched powders obtained are mixed using a mixer-mixer. These capsules can even be blistered. The liquid form The different powders are weighed and taken in appropriate quantities, the mixture is made in a large container, and then a solvent is added. The solid and liquid pharmaceutical compound has an anti-androgenic action by inhibiting the isoforms 1 and 2 of 5-alpha-reductase, a potent anti-inflammatory synergistic through its various components by inhibiting: -The activity phospholipase A2, the lipo-oxygenase activity and cyclo-oxygenase activity It has an antiproliferative action by inhibiting: growth factor-induced proliferation BFGF, EGF, EGF concentration The solid and liquid pharmaceutical compound has an anesthetic action by suppressing cancer warning chains The solid and liquid pharmaceutical compound has an anesthetic action by reducing the access routes and irrigation of cancer cells that can no longer find the foods necessary for their development. |
| priorityDate | 2014-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.